New York State Common Retirement Fund Aeglea Bio Therapeutics, Inc. Transaction History

New York State Common Retirement Fund

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 04, 2022	SELL	$0.5 - $2.66 $8,350 - $44,422	-16,700 Reduced 98.0%	341 $0
Q4 2021 Feb 02, 2022	SELL	$3.5 - $8.42 $133 - $319	-38 Reduced 0.22%	17,041 $81,000
Q3 2021 Nov 02, 2021	SELL	$6.03 - $7.95 $86,862 - $114,519	-14,405 Reduced 45.75%	17,079 $136,000
Q2 2021 Aug 02, 2021	BUY	$6.32 - $8.38 $2,426 - $3,217	384 Added 1.23%	31,484 $219,000
Q4 2020 Feb 08, 2021	SELL	$7.02 - $9.83 $51,246 - $71,759	-7,300 Reduced 19.01%	31,100 $245,000
Q2 2020 Aug 07, 2020	BUY	$4.01 - $11.04 $78,195 - $215,279	19,500 Added 103.17%	38,400 $355,000
Q4 2019 Feb 05, 2020	SELL	$7.23 - $8.55 $56,394 - $66,690	-7,800 Reduced 29.21%	18,900 $144,000
Q3 2019 Nov 07, 2019	SELL	$6.42 - $9.0 $642 - $900	-100 Reduced 0.37%	26,700 $205,000
Q2 2019 Aug 09, 2019	BUY	$6.1 - $8.78 $111,020 - $159,796	18,200 Added 211.63%	26,800 $184,000
Q3 2018 Nov 07, 2018	SELL	$8.24 - $11.0 $78,280 - $104,500	-9,500 Reduced 52.49%	8,600 $82,000
Q2 2018 Aug 10, 2018	BUY	$7.87 - $10.89 $142,447 - $197,109	18,100 New	18,100 $191,000

241K

Ticker AGLE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,172,500
Market Cap $1.69B
Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...

Get notified when there are updates to the investment portfolio of New York State Common Retirement Fund, based on Form 13F filings with the SEC.

Stay updated on New York State Common Retirement Fund with notifications on news.